# A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

> **NCT06521931** · PHASE1 · COMPLETED · sponsor: **Chongqing Peg-Bio Biopharm Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** PN20

## Key facts

- **NCT ID:** NCT06521931
- **Lead sponsor:** Chongqing Peg-Bio Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-06
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06521931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06521931, "A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06521931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*